BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 728K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

10 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.EBI
Johann Wolfgang Goethe University
Assessment of the structure-activity relationship and antileukemic activity of diacylpyramide compounds as human ClpP agonists.EBI
University of Chinese Academy of Sciences
Discovery of Dehydrogenated Imipridone Derivatives as Activators of Human Caseinolytic Protease P.EBI
China Pharmaceutical University
Rational Design of a Novel Class of Human ClpP Agonists through a Ring-Opening Strategy with Enhanced Antileukemia Activity.EBI
Sichuan University
Discovery of a Novel Series of Homo sapiens Caseinolytic Protease P Agonists for Colorectal Adenocarcinoma Treatment via ATF3-Dependent Integrated Stress Response.EBI
Sichuan University
Discovery of 5-(Piperidin-4-yl)-1,2,4-oxadiazole Derivatives as a New Class of Human Caseinolytic Protease P Agonists for the Treatment of Hepatocellular Carcinoma.EBI
Sichuan University
The evolution of small molecule enzyme activators.EBI
University of Nebraska
Discovery of a Novel Series of Imipridone Compounds as EBI
Sichuan University
Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities.EBI
Sichuan University
De Novo Design of Boron-Based Peptidomimetics as Potent Inhibitors of Human ClpP in the Presence of Human ClpX.EBI
University of Toronto